MedTrace Logo

Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

NCT06180759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-04-02

No results posted yet for this study

Summary

N,N-dimethyltryptamine (DMT) is a classical psychedelic with similar effects like LSD or psilocybin. Preliminary evidence from case series and small open-label trials suggests that psychedelics may be promising candidates for the treatment of several pain-related diseases such as chronic pain, migraine, cluster headache or phantom limb pain. However, data from rigorously conducted and randomized clinical trials are lacking. Additionally, the potential acute analgesic properties of psychedelics remain poorly characterized. Therefore, the investigators will evaluate the efficacy of DMT on different pain qualities within a model of electrically induced pain in healthy participants. The analgesic effects will be compared to racemic ketamine (active control) and placebo within a cross-over design.

Conditions

  • Healthy

Interventions

DRUG

Intravenous infusion of DMT

A dose rate of 1.2 mg/min will be administered

DRUG

Intravenous infusion of ketamine

A dose rate of 1.0 mg/min will be administered

DRUG

Intravenous infusion of placebo

A Placebo (saline infusion) will be administered.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2025-09-29
Completion
2025-11-06

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06180759 on ClinicalTrials.gov